Telix Pharmaceuticals Ltd
TLX7.140USD
-0.290-3.90%
종가 02/03, 16:00（ET）시세는 15분 지연됩니다
0.00시가총액
--P/E TTM
자세한 내용은 Telix Pharmaceuticals Ltd 회사
Telix Pharmaceuticals Limited is an Australia-based biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. It is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. Its segments include Therapeutics, Precision Medicine and Telix Manufacturing Solutions. Therapeutics segment develops targeted radionuclide therapies for urologic, neurologic, musculoskeletal and hematological cancers. Precision Medicine segment focuses on bringing diagnostic imaging solutions to market. Precision Medicine segment also includes MedTech and International businesses. Telix Manufacturing Solutions segment is its global network of facilities designed to deliver patient doses worldwide. Its pipeline products include TLX591, TLX250, TLX101, TLX66, TLX592, TLX252, TLX400, Illuccix (68Ga-PSMA-11) and TLX007-CDx.
Telix Pharmaceuticals Ltd 정보
종목 코드 TLX
회사 이름Telix Pharmaceuticals Ltd
상장일Nov 15, 2017
CEOOrtiz (Raphaeel)
직원 수- -
유형Depository Receipt
회계 연도 종료- -
주소55 Flemington Road
도시MELBOURNE
증권 거래소NASDAQ OMX - NASDAQ BASIC
국가Australia
우편 번호3051
전화61390933855
웹사이트https://telixpharma.com/
종목 코드 TLX
상장일Nov 15, 2017
CEOOrtiz (Raphaeel)
Telix Pharmaceuticals Ltd의 회사 임원진
이름
이름/직위
직위
주식 보유
변동
Dr. Christian P. Behrenbruch, J.D., Ph.D.
Dr. Christian P. Behrenbruch, J.D., Ph.D.
Group Chief Executive Officer, Managing Director, Executive Director
Group Chief Executive Officer, Managing Director, Executive Director
--
--
Dr. Mark Nelson, Ph.D.
Dr. Mark Nelson, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Jann Skinner
Ms. Jann Skinner
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. David Cade
Dr. David Cade
Group Chief Medical Officer
Group Chief Medical Officer
--
--
Mr. Richard Valeix
Mr. Richard Valeix
Group Chief Commercial Officer
Group Chief Commercial Officer
--
--
Ms. Tiffany P. Olson
Ms. Tiffany P. Olson
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Mr. Darren Smith, CPA
Mr. Darren Smith, CPA
Group Chief Financial Officer
Group Chief Financial Officer
--
--
Mr. Kevin Richardson
Mr. Kevin Richardson
Chief Executive Officer - Telix Precision Medicine
Chief Executive Officer - Telix Precision Medicine
--
--
Mr. Raphaeel Ortiz
Mr. Raphaeel Ortiz
Chief Executive Officer - Telix International
Chief Executive Officer - Telix International
--
--
Ms. Genevieve Ryan
Ms. Genevieve Ryan
Company Secretary
Company Secretary
--
--
더 보기
이름
이름/직위
직위
주식 보유
변동
Dr. Christian P. Behrenbruch, J.D., Ph.D.
Dr. Christian P. Behrenbruch, J.D., Ph.D.
Group Chief Executive Officer, Managing Director, Executive Director
Group Chief Executive Officer, Managing Director, Executive Director
--
--
Dr. Mark Nelson, Ph.D.
Dr. Mark Nelson, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Jann Skinner
Ms. Jann Skinner
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. David Cade
Dr. David Cade
Group Chief Medical Officer
Group Chief Medical Officer
--
--
Mr. Richard Valeix
Mr. Richard Valeix
Group Chief Commercial Officer
Group Chief Commercial Officer
--
--
Ms. Tiffany P. Olson
Ms. Tiffany P. Olson
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
수익 분석
기업이 아직 관련 데이터를 공개하지 않았습니다.
기업이 아직 관련 데이터를 공개하지 않았습니다.
사업별
지역별
기업이 아직 관련 데이터를 공개하지 않았습니다.
주식 보유 통계
마지막 업데이트: Sun, Jan 18
마지막 업데이트: Sun, Jan 18
주주
주주 유형
주주
주주
비율
Millennium Management LLC
0.06%
Portland Investment Counsel Inc.
0.04%
Fidelity Management & Research Company LLC
0.04%
Lazard Asset Management, L.L.C.
0.03%
Jane Street Capital, L.L.C.
0.02%
기타
99.81%
주주
주주
비율
Millennium Management LLC
0.06%
Portland Investment Counsel Inc.
0.04%
Fidelity Management & Research Company LLC
0.04%
Lazard Asset Management, L.L.C.
0.03%
Jane Street Capital, L.L.C.
0.02%
기타
99.81%
주주 유형
주주
비율
Investment Advisor
0.11%
Hedge Fund
0.06%
Investment Advisor/Hedge Fund
0.05%
Research Firm
0.02%
기타
99.76%
기관 주식 보유
마지막 업데이트: Thu, Jan 1
마지막 업데이트: Thu, Jan 1
보고 기간
기관 수
보유 주식
비율
변동
2025Q4
40
844.56K
0.25%
+354.04K
2025Q3
25
456.14K
0.13%
+379.51K
2025Q2
11
269.45K
0.08%
+265.72K
2025Q1
6
20.71K
0.01%
+16.98K
2024Q4
1
3.73K
0.00%
+3.73K
주주 활동
이름
보유 주식
비율
변동
Chg %
날짜
Millennium Management LLC
196.74K
0.06%
+196.74K
--
Sep 30, 2025
Portland Investment Counsel Inc.
128.00K
0.04%
+128.00K
--
Sep 30, 2025
Fidelity Management & Research Company LLC
118.48K
0.04%
+76.39K
+181.48%
Sep 30, 2025
Lazard Asset Management, L.L.C.
114.62K
0.03%
+114.62K
--
Sep 30, 2025
Jane Street Capital, L.L.C.
72.99K
0.02%
+37.89K
+107.94%
Sep 30, 2025
Marshall Wace LLP
48.57K
0.01%
+48.57K
--
Sep 30, 2025
Private Advisor Group LLC
42.11K
0.01%
+16.95K
+67.33%
Sep 30, 2025
IHT Wealth Management, LLC
26.21K
0.01%
+12.97K
+97.95%
Sep 30, 2025
JPMorgan Private Bank (United States)
25.36K
0.01%
+25.36K
--
Sep 30, 2025
Vanguard Personalized Indexing Management, LLC
18.38K
0.01%
-97.00
-0.53%
Sep 30, 2025
더 보기
관련 ETF
이름
비율
데이터 없음
주식 배당금
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.
날짜
배당금
기준일
지급일
배당락일
데이터 없음
주식 분할
날짜
배당락일
유형
비율
데이터 없음
날짜
배당락일
유형
비율
데이터 없음
